Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.

By Iňigo Landa, Tihana Ibrahimpašić, Laura Boucai, Rileen Sinha, J. Knauf, Ronak H. Shah, S. Dogan, Julio C. Ricarte-Filho, Gnana P. Krishnamoorthy, Bin Xu and 7 more. Journal of Clinical Investigation, 2016

1,023 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/8c79eb5a29df9ae0823763e5d84b157cf8874bb4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Gautam Sethi
2. D. Fruman

Citations in the corpus

• PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer (2023, background): “PTEN loss-of-function alterations, especially deletion, are also detected in brain cancer [87], glioblastoma multiforme [99], anaplastic/ poorly differentiated thyroid cancer [85], SCLC, NSCLC [77], melanoma [69], oesophageal cancer [100], gallblad-”
• Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2019, background): “Other rare mutations and genetic aberrations may also prove to be druggable, such as ALK translocations [21, 22].”
• Overview of the 2022 WHO Classification of Thyroid Neoplasms (2022, background): “The other molecular events seen in TC-PTC include loss of heterozygosity for chromosome 1 and TP53 mutations [110].”